PRE — Prenetics Global Limited

Summary of Prenetics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $36.6 million, a 457% increase year-over-year and a 55% sequential increase from Q3.
• Full Year Revenue: $92.4 million, up approximately 480% from 2024.
• Q4 Gross Profit: $21.7 million with a gross margin of 59%, representing an 804% increase year-over-year.
• Full Year Gross Profit: $48.9 million, a 428% increase.
• Adjusted EBITDA Loss: Q4 loss of $2.3 million (70.4% improvement year-over-year) and a full-year loss of $13 million (27% improvement).
• IM8 Revenue: Contributed $27.4 million in Q4 and $60.1 million for the full year, with a gross margin of 63%.

2. Strategic Updates and Business Highlights

• Transformation: Prenetics completed a strategic pivot to focus solely on consumer health, divesting non-core assets, including ACT Genomics for $72 million and a stake in Insighta for $70 million.
• IM8 Launch: The premium health brand co-founded with David Beckham achieved a $120 million annualized revenue run rate within its first year, with significant international sales (40% U.S., 60% international).
• Customer Acquisition: The introduction of quarterly subscriptions has doubled the average order value from $110 to $233, enhancing cash flow and customer retention.
• Research Coverage: Initiated by ROTH Capital and Sidoti & Company, both with buy ratings and price targets of $36 and $30, respectively.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected IM8 revenue of $180 million to $200 million, representing nearly 300% year-over-year growth.
• Gross Margin Target: Approximately 60% for full-year 2026.
• Adjusted EBITDA Loss Guidance: Projected loss of $16 million to $20 million for 2026, with a path to profitability by Q4 2027.

4. Bad News, Challenges, or Points of Concern

• Adjusted EBITDA Loss: Despite improvements, the company still reported a significant adjusted EBITDA loss, indicating ongoing investment needs.
• Customer Acquisition Costs (CAC): While CAC has remained stable, the increase in average order value suggests a potential risk if customer acquisition costs rise disproportionately in the future.
• Market Competition: The company faces competitive pressures in the health supplement market, particularly with upcoming product launches from competitors.

5. Notable Q&A Insights

• Customer Acquisition Strategy: The company emphasized a focus on new customer acquisition, with significant potential for growth in untapped markets.
• AI Utilization: Prenetics is leveraging AI for digital marketing, optimizing ad performance, and enhancing customer engagement.
• Product Launches: Two new SKUs are expected by the end of Q4 2026, targeting large addressable markets, but these are not included in the current revenue guidance.
• Localization Efforts: Plans to localize websites in five markets are anticipated to boost revenue by 10-15% in those regions.

Overall, Prenetics is positioned for significant growth driven by its IM8 brand, but it must navigate ongoing losses and competitive pressures while executing its strategic initiatives.